In 2008, he funded VisMederi srl, a private enterprise involved in management and serology for clinical trials and focussed studies with human viruses for pharmaceutical companies. Actually, he has a role of Chief Scientific Officer.
His research interest is primarily in the field of influenza vaccines, and in particular in the study of correlates of protection. He is expert in development, standardization and validation of assays for antibody detection. He has conducted many clinical and laboratory research studies to evaluate immunogenicity and efficacy of traditional and new influenza vaccines. Recently he has participated in protocols for development and evaluation of new molecules as adjuvants. He has also undertaken planning and execution of European seroepidemiological studies for emerging infectious disease in collaboration with WHO Regional Office and eCDC.
He has participated in several analyses for COVID-19 vaccines evaluation, and conducted the VisMederi laboratories as part of the CEPI international network.
In 2015, he was Scientific Coordinator for one European Project IMI (Innovative Medicine Initiative) titled “Standardization and development of assays for assessment of influenza vaccine correlates of protection (FLUCOP)” (IMI-JU-10-2013-01, Grant Agreement No 115672).
He has organized 1st, 2nd and 3rd edition of the Summer School on influenza in Siena with the support of ISIRV.Over the years, he has published more than 1000 scientific papers and reviews, and written several chapters in textbooks.